Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) has a dated narrative snapshot, but its priced-in model claim is temporarily suppressed because the model-solve record is unavailable or has changed.
233 institutional managers reported holding DNTH in 13F filings for the quarter ended 2026-03-31. 90 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 7.0M shares were sold short as of the 2026-06-15 count, about 15% of shares outstanding (5.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at DNTH over the trailing three years: 2023: 7 buys totaling $1.45M. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DNTH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-05-17 | +3.5% | +70.5% |
| 2022-08-05 | +14.2% | -32.8% |
| 2023-03-24 | +1.8% | -17.8% |
| 2023-05-16 | -11.6% | +18.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DNTH's latest 8-K filings: 2026-06-12 (items 8.01, 9.01); 2026-05-22 (items 5.07); 2026-05-05 (items 2.02, 9.01); 2026-03-26 (items 8.01, 9.01); 2026-03-12 (items 1.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.